Background
==========

The only method for definitive diagnosis of Alzheimer\'s disease (AD) to date is postmortem examination of the brain. Current understanding indicates that the neuropathological hallmarks, senile plaques (SP) and neurofibrillary tangles (NFT) develop within the brain, interrupting neuronal signalling and causing the irreversible symptoms of memory impairment and gradual cognitive decline \[[@B1],[@B2]\]. Efforts to prevent or slow the disease are hampered by a lack of understanding as to how these neuropathological hallmarks develop and actually cause the disease - if they do.

There are two forms of AD - familial and sporadic - of which the sporadic is much more common, comprising 96% of all cases. Familial AD (FAD) is mostly caused by mutations in 3 particular genes (amyloid precursor protein, presenilin 1 and presenilin 2) \[[@B3]\], which are directly related to the formation of SP. This has lead researchers to believe that SP are the main culprit in all forms of AD. Many studies have revealed environmental and genetic factors that affect the risk of sporadic AD, such as exercise, education level and the ε4 allele of *APOE*\[[@B4]\].

At present, the apolipoprotein E (*APOE*) ε4 allele is the only commonly accepted gene known to confer increased risk for sporadic AD, whilst the rare ε2 allele is believed to convey protection. Various studies have found ORs of between 2 and 8, as well as lowering the age of onset, with ε4 allele dosage \[[@B5],[@B6]\]. Recently, genome wide association studies \[[@B7]-[@B9]\] have revealed some lower impact genes that may increase AD risk, possibly accounting for a part of the remaining unexplained \~50% of genetic risk effects. Many other genes have also been suggested to increase the risk of AD, but the evidence has been conflicting, with *APOE*being the only consistent association.

The possible connection between AD and inflammation was ignited by a study \[[@B10]\] showing a reduced incidence of AD in a cohort of rheumatoid arthritic patients taking non-steroidal anti-inflammatory drugs (NSAIDs), however other studies have disputed this connection \[[@B11]\]. New research \[[@B12]-[@B14]\] supports this, as many inflammatory markers have been found localised with the neuropathological characteristics of AD; these include neuroinflammatory cells, astrocytes, and microglia. Recent genome wide association studies have also shed light on this, with inflammatory genes being put in the spotlight \[[@B9]\]. It has also been suggested that chronic inflammation in the brain from various bacterial/viral diseases could contribute to the disease \[[@B15],[@B16]\]. Interactions between inflammatory gene polymorphisms and invading pathogens have also been proposed to participate in disease manifestation \[[@B17]\]. The question remains, however, whether the inflammatory processes are a cause or consequence of the disease, as a majority of previous studies have been conducted in advanced stage AD cases.

C-reactive protein (CRP) is an acute phase inflammatory marker found in plasma, primarily produced by the liver to combat pathogens through activation of immune responses \[[@B18]\]. Additionally, CRP activates the cleanup of cellular debris through its action as a pattern recognition receptor involving calcium-dependent ligand binding \[[@B19]\]. Its role in AD has already been suggested by work by Yasojima et al., which showed that CRP production is upregulated in affected areas of AD brains \[[@B20]\].

Some single nucleotide polymorphisms (SNPs) of the *CRP*gene have been shown to associate with higher CRP levels. One of the most influential of these polymorphisms, identified in a genome-wide association study, was rs3091244 (T and A alleles), as well as others; rs1130864 (T allele), rs1205 (G allele) and rs3093075 (C allele)\[[@B21]-[@B23]\]. The SNP rs2794521 (T allele) has been reported to increase transcription of the *CRP*allele \[[@B24],[@B25]\]. Haplotypes associated with 2-3-fold increases in CRP levels correlate with poorer survival in general of elderly subjects \[[@B22]\]. Lower CRP levels have been associated with the C allele of SNP rs1800947 \[[@B21],[@B26],[@B24],[@B27]\] and common haplotypes of the gene are also associated with serum CRP concentration \[[@B24]\].

We have shown previously that accumulation of AD neuropathological lesions is unexpectedly common, with 31.1% of individuals living outside institutions having SP and 42.1% having NFT \[[@B28]\]. This accumulation starts already around 30 years of age, especially among the carriers of the *APOE*ε4 allele, reaching an occurrence of almost 100% in the oldest. Other studies have also shown associations with the *APOE*ε4 allele and both SP and NFT \[[@B29],[@B30]\].

We hypothesised that individuals with *CRP*genotypes associated with higher CRP production would be more likely to show development of SP already in the prodromal phase before the development of clinical AD. At the least, these phenomena might participate in the early stages in the development of the lesions. We explored potential associations between the *CRP*gene and the brain changes commonly linked to AD in a large autopsy cohort representing a population living outside institutions, of which the majority were non-AD patients who died mainly out-of-hospital. As far as we are aware, this is the first study that has looked at the association between AD pathology and CRP, both at a genetic and cellular level.

Methods
=======

Cohort
------

The Tampere Autopsy Study (TASTY) cohort comprises 603 men and women aged 0 - 97 years who were subjected to medico-legal autopsy and generally died out-of-hospital in Finland during the years 2002-2004, representing around 4% of deaths in the Tampere region. None died of AD causes, although 6 (\< 1%) were clinically diagnosed with AD during life, 22 (3.7%) were demented and 10 (1.7%) had memory problems. Recorded causes of death are given in table [1](#T1){ref-type="table"}; more detailed causes of death are not available. Further data on illnesses and/or medication use during life are not accessible to the researchers. Autopsies were performed by the department of Forensic Medicine at the University of Tampere and data pertaining to the cases were obtained from doctors and family members where possible. The study was approved by the Board of Medicolegal Affairs of Finland.

###### 

The Tampere Autopsy Study (TASTY) characteristics

  *Number of cases*     603
  --------------------- ---------------------------
  *Gender*              
  *Males*               388 (64.3%)
  *Females*             215 (35.7%)
  *Age (years)^1^*      62.7 (range 0 - 96.7)
  *Cause of Death*      
  *Disease*             340 (56.5%)
  *Accident*            177 (29.5%)
  *Suicide*             72 (12.0%)
  *Homicide*            3 (0.5%)
  *Unknown*             9 (1.5%)
  *Brain Mass (g)^1^*   1408.1 (range 427 - 1910)
  *Dementia Status*     
  *Normal*              570 (94.5%)
  *AD*                  6 (0.9%)
  *Dementia*            16 (2.7%)
  *Memory Problems*     10 (1.7%)
  *Parkinson\'s Dis*    1 (0.2%)
  *APOE Genotype*       
  *APOEε3ε3*            356 (59.2%)
  *APOEε2ε3, ε2ε2*      58 (9.7%)
  *APOEε4+*             187 (31.1%)
  *SP Presence*         
  *No*                  381 (68.9%)
  *Yes*                 172 (31.1%)
  *CERAD score*         
  *\< 0%*               379
  *0 - 1.053%*          85
  *1.053% +*            85
  *NFT Presence*        
  *No*                  280 (57.9%)
  *Yes*                 204 (42.1%)

*^1^*- statistical mean.

Senile plaques and neurofibrillary tangles
------------------------------------------

SP and NFT assessments were made as previously described \[[@B28]\]. A large number (70%) of cases had \'no SP\' and using this skewed data as a continuous variable would make analyses invalid; therefore we categorised the SP into the following categorisations: ≥1 SP (yes/no), and SP typing (no SP, non-neuritic SP (diffuse/primitive), neuritic SP (classic/burnt out)). Analyses also investigated SP density in a semi-quantitative manner, dividing SP counts into \'no SP\', \'sparse SP\', \'moderate SP\' and \'frequent SP\', comprising a scoring system based on the CERAD protocol (but without age adjustment). We categorised NFT as: ≥1 NFT (yes/no). NFT and SP were defined by a neuropathologist assessing grid regions of complete brain samples on Bielschowsky-stained slides of frontal cortex (SP) and hippocampus (NFT) in each case. In our cohort, females were older on average by 10 years, causing the category of gender to represent age, however analyses showed similar results when split by gender. Therefore gender was excluded as a covariate in our analyses.

Tissue microarrays
------------------

Tissue microarrays (TMAs) were also constructed (as described in \[[@B28]\]), to allow easier and simultaneous analysis of multiple cases, and held approximately 10-14 cases per block. TMAs were utilised for immunohistochemistry for CRP and Aβ staining. Brain regions that were incorporated into the TMAs were the hippocampal regions CA1, CA2, CA3, and CA4; cerebellum, neocortex (frontal lobe), gyrus cinguli and cerebrum (white matter). Technical difficulties and sample damage precluded inclusion of all TASTY cases, but 92.5% were incorporated.

Genotyping
----------

CRP genotyping was performed at Biomedicum, Helsinki (MA) on the Sequenom MassArray system with the homogeneous Mass Extension (hME) reaction (Sequenom, San Diego, USA) for 6 reported haplotype tagging single nucleotide polymorphisms (SNPs), including rs2794521 (T \> C), rs3091244 (C \> T \> A), rs1800947 (G \> C), rs1130864 (C \> T), rs1205 (C \> T) and rs3093075 (C \> A). Haplotyping was calculated with 5 SNPs (SNP order: rs2794521, rs3091244, rs1800947, rs1130864 and rs1205; rs3093075 was excluded as it produced too many low prevalence haplotypes) using the PHASE program \[[@B31],[@B32]\] (version 2.1.1) and indicated five haplotypes with prevalence above 5%.

Immunohistochemistry
--------------------

Fluorescent immunohistochemical (F-IHC) staining was performed on the TASTY-TMAs in the hippocampal CA1/2 area and utilised DAPI (Sigma-Aldrich, Germany), rabbit anti-CRP (BioLegend, USA), mouse anti-Aβ (Acris Antibodies, Germany), anti-mouse IgG FITC conjugated (Novus Biologicals, USA), anti-rabbit IgG rhodamine conjugated (Antibodies-online, Germany), all according to manufacturer\'s instructions. For analyses, cases were assessed as positive or negative for staining.

Statistics
----------

Statistical analyses were performed with an SPSS program (version 14.0). Analyses for CRP SNPs and haplotypes used the most common genotype or previously reported \'risk\' allele as the reference group and included APOE4 carriership and age as covariates where possible. Their associations were analysed using logistic regression. Chi square analysis was used to determine association with IHC staining. False discovery rate (FDR) multiple correction calculations were performed assuming there were 11 independent tests (6 SNPs and 5 haplotypes), using the calculation below and assuming an FDR value of \< 0.05 was acceptable.

Results
=======

Cohort
------

The Tampere Autopsy Study (TASTY) (Table [1](#T1){ref-type="table"}) consisted of 603 autopsy cases (35.7% females) of subjects who died mainly out-of-hospital over a three year period. Data on memory problems or possible dementia were collected from hospital records and/or next of kin. Of the series 558 cases (92.5%) were included in the brain tissue microarray (TMA) construction. Not all samples were included due to data discrepancies, technical issues and sample decay/damage.

Senile plaques and neurofibrillary tangles
------------------------------------------

Senile plaque (SP) frequency was available for 553 (90.9%), and neurofibrillary tangle (NFT) counts for 484 (80.3%). Both lesions were positively associated with age \[[@B28]\].

Genotyping
----------

*APOE*genotyping was performed on 601 cases and *CRP*genotypes were acquired for 537 cases (89%). *APOE*and *CRP*genotyping indicated that there were no significant differences in the distribution of allele frequencies in each age group, and that they followed Hardy-Weinberg proportions.

Associations between genotypes and neuropathological lesions
------------------------------------------------------------

Univariate logistic regression analysis showed that the SNP rs2794521 (p = 0.067) was associated with SP prevalence (yes/no SP presence). However, including age and *APOE4*carriership as covariates weakened the association (p = 0.096).

When we took into account the phenotype of SP (Table [2](#T2){ref-type="table"}), two high-CRP level-linked SNPs - rs3091244 (TA carriers; OR 6.7, p = 0.007) and rs3093075 (CA carriers; OR 3.5, p = 0.003) - appeared to convey increased risk for early non-neuritic SP compared to no SP. There was also a tendency towards increased risk for late neuritic SP (OR 4.5, p = 0.072; OR 2.1, p = 0.080, respectively).

###### 

Multivariate logistic regression for SP type (no SP - reference group, non-neuritic SP and neuritic SP) and association with *CRP*SNPs (*APOE4*carriership and age were included as covariates)

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                           Non-Neuritic SP    Neuritic SP                                                                                              
  ----------- ------ ------------ ----------- ------------ ------------------ ------------- -------- ----------------- ------------------ -------- -------- --------- ---------------- -------
                     **Assoc**.   **Total**   **Prev %**   **Affected (%)**   **OR**        **CI**   ***p***           **Affected (%)**   **OR**   **CI**   ***p***                    

                                                                                                                                                                                       

  rs2794521   TT\*   T allele\    321         60.8         36                 11.2          1        Ref               \-                 68       21.2     1         Ref              \-
                     - high                                                                                                                                                            

              CC                  25          4.7          2                  8.0           0.673    0.142 - 3.200     0.619              8        32.0     1.265     0.410 - 2.272    0.683

              CT                  182         34.5         13                 7.1           0.433    0.197 - 0.952     0.037^a^           26       14.3     0.600     0.317 - 1.138    0.118

                                                                                                                                                                                       

  rs3091244   CC\*   T & A\       179         33.7         18                 10.1          1        Ref               \-                 32       17.9     1         Ref              \-
                     alleles\                                                                                                                                                          
                     - high                                                                                                                                                            

              TT                  73          13.7         2                  2.7           0.290    0.063 - 1.334     0.112              19       26.0     1.829     0.786 - 4.254    0.161

              TA                  16          3.0          5                  31.3          6.717    1.673 - 26.978    0.007^a^           3        18.8     4.535     0.873 - 23.555   0.072

              CA                  41          7.7          7                  17.1          1.771    0.606 - 5.172     0.296              9        22.0     2.117     0.730 - 6.139    0.167

              AA                  3           0.6          0                  0             .        .                 .                  0        0        .         .                0.998

              TC                  219         41.2         20                 9.1           0.819    0.384 - 1.744     0.604              40       18.3     1.179     0.589 - 2.361    0.642

                                                                                                                                                                                       

  rs1800947   GG\*   C allele\    457         86.4         43                 9.4           1        Ref               \-                 89       19.5     1         Ref              \-
                     - low                                                                                                                                                             

              CC                  5           0.9          1                  20.0          7.107    0.419 - 120.535   0.175              2        40.0     3.814     0.160 - 90.798   0.408

              GC                  67          12.7         7                  10.4          1.428    0.579 - 3.526     0.439              12       17.9     0.700     0.270 - 1.813    0.463

                                                                                                                                                                                       

  rs1130864   CC\*   T allele\    220         42.2         25                 11.4          1        Ref               \-                 40       18.2     1         Ref              \-
                     - high                                                                                                                                                            

              TT                  72          13.8         2                  2.8           0.258    0.058 - 1.154     0.076              19       26.4     1.645     0.738 - 3.666    0.224

              TC                  229         44.0         24                 10.5          0.898    0.461 - 1.748     0.751              43       18.8     1.185     0.630 - 2.229    0.599

                                                                                                                                                                                       

  rs1205      TT\*   C allele\    65          12.3         9                  13.8          1        Ref               \-                 12       18.5     1         Ref              \-
                     - high                                                                                                                                                            

              CC                  224         42.5         15                 6.7           0.397    0.154 - 1.025     0.056              51       22.8     1.492     0.584 - 3.814    0.403

              CT                  238         45.2         28                 11.8          0.675    0.281 - 1.623     0.380              40       16.8     0.949     0.363 - 2.478    0.914

                                                                                                                                                                                       

  rs3093075   CC\*   C allele\    469         88.7         39                 8.3           1        Ref               \-                 91       19.4     1         Ref              \-
                     - high                                                                                                                                                            

              AA                  3           0.6          0                  0             .        .                 .                  0        0        .         .                .

              CA                  57          10.8         12                 21.1          3.492    1.545 - 7.894     0.003^a^           12       21.1     2.143     0.914 - 5.022    0.080
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\* denotes the most common homozygous genotype acting as the reference group in analyses.

. denotes the values were unable to be computed.

^a^denotes statistically significant values.

Non-neuritic SP are diffuse and primitive SP grouped together, neuritic SP are classic and burnt out SP grouped together; as measured by a neuropathologist.

Prev % refers to prevalence of alleles.

Assoc. refers to associations with CRP levels.

CRP = c-reactive protein gene, SNPs = single nucleotide polymorphisms, SP = senile plaques, OR = odds ratio, CI = confidence interval, *p*= p value.

On the contrary, carriers of the low-CRP level-linked C allele of SNP rs2794521 (OR 0.46, CI 0.22 - 0.96, p = 0.039) were less likely to have non-neuritic SP, derived from an association with the common CT genotype (OR 0.43, p = 0.037). A trend towards the same associations was seen with neuritic SP. Conversely, the high-CRP level SNPs rs1130864 (TT carriers; OR 0.26, p = 0.076) and rs1205 (CC carriers; OR 0.39, p = 0.056) showed a non-significant trend towards protection for non-neuritic compared to no SP.

In multivariate logistic regression, *CRP*haplotypes composed of alleles related to high-CRP levels, such as TAGCC, were associated with presence of non-neuritic SP (OR 2.99, p = 0.007), significantly increasing the risk of occurrence (Table [3](#T3){ref-type="table"}). On the contrary, haplotype carriership of alleles linked with lower CRP levels, such as CCGCC, reduced (OR 0.45, p = 0.034) the likelihood of possessing non-neuritic SP. Similar, but-non significant tendencies towards these associations were also seen for both haplotypes and neuritic SP.

###### 

Multivariate logistic regression results for SP type (no SP - reference group, non-neuritic SP and neuritic SP) and association with *CRP*haplotypes (*APOE4*carriership and age were included as covariates)

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                        Non-Neuritic SP    Neuritic SP                                                                                            
  ------- ------- ------------ ----------- ------------ ------------------ ------------- -------- --------------- ------------------ -------- -------- --------- ---------------- -------
                  **Assoc**.   **Total**   **Prev %**   **Affected (%)**   **OR**        **CI**   ***p***         **Affected (%)**   **OR**   **CI**   ***p***                    

                                                                                                                                                                                  

  TTGTC   Yes\*   High-CRP     306         37.0         26                 8.5           1        Ref             \-                 62       20.3     1         Ref              \-

  \(1\)   No                   225                      26                 11.6          1.402    0.740 - 2.656   0.300              41       18.2     0.776     0.435 - 1.383    0.390

  TCGCC   No\*    No assoc.    516                      52                 10.1          1        Ref             \-                 96       18.6     1         Ref              \-

  \(3\)   Yes                  15          1.2          0                  0.0           .        .               .                  7        46.7     4.124     0.700 - 24.278   0.117

  TCGCT   No\*    No assoc.    282                      22                 7.8           1        Ref             \-                 61       21.6     1         Ref              \-

  \(4\)   Yes                  249         30.0         30                 12.0          1.397    0.736 - 2.651   0.307              42       16.9     0.686     0.386 - 1.217    0.197

  TCCCT   No\*    Low-CRP\     459                      44                 9.6           1        Ref             \-                 89       19.4     1         Ref              \-
                  in females                                                                                                                                                      

  \(5\)   Yes                  72          6.6          8                  11.1          1.545    0.655 - 3.644   0.321              14       19.4     0.775     0.312 - 1.923    0.582

  TAGCC   No\*    High-CRP     471                      40                 8.5           1        Ref             \-                 91       19.3     1         Ref              \-

  \(6\)   Yes                  60          5.2          12                 20.0          2.985    1.342 - 6.638   0.007^a^           12       20.0     1.809     0.785 - 4.167    0.164

  CCGCC   No\*    Low-CRP\     324                      37                 11.4          1        Ref             \-                 69       21.3     1         Ref              \-
                  in males                                                                                                                                                        

  \(7\)   Yes                  207         19.5         15                 7.2           0.453    0.218 - 0.941   0.034^a^           34       16.4     0.680     0.376 - 1.228    0.201
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\* denotes the most common haplotype acting as the reference group in analyses.

. denotes the values were unable to be computed.

^a^denotes statistically significant values.

Numbers in brackets referring to our own number allocation system for haplotypes.

Haplotypes consist of SNPs rs2794521 (T \> C), rs3091244 (C \> T \> A), rs1800947 (G \> C), rs1130864 (C \> T) and rs1205 (C \> T).

Non-neuritic SP are diffuse and primitive SP grouped together, neuritic SP are classic and burnt out SP grouped together; as measured by a neuropathologist.

Prev % refers to prevalence of alleles.

Assoc. refers to associations with CRP levels.

CRP = c-reactive protein gene, SP = senile plaques, N = Number of cases, OR = odds ratio, CI = confidence interval, *p*= p value.

Haplotype pair analyses compared all haplotype pairs with prevalence above 6% against the most common pair (TTGTC/TCGCT). None of the haplotype pairs were associated with SP prevalence. Analyses with SP phenotype suggested a trend towards protection for the haplotype pair TTGTC/TTGTC (p = 0.065) and TCGCT/CCGCC (p = 0.070) with non-neuritic SP, although the association weakened with the inclusion of age and *APOE4*carriership as covariates (data not shown).

NFT prevalence (yes/no presence) showed an association only with SNP rs2794521, using univariate logistic regression (p = 0.059). Inclusion of *APOE*genotype and age as covariates weakened the association (p = 0.107).

Semi-quantitative analyses of SP density did not reveal any significant associations with any of the *CRP*genotypes, and splitting the data by gender did not provide any additional results (data not shown).

Immunohistochemistry
--------------------

CRP IHC staining (positive/negative) was found to be significantly correlated with Aβ (amyloid-β) staining (positive/negative) in all studied brain regions in the cohort, (Chi square p \< 0.0001, Figure [1](#F1){ref-type="fig"}). Aβ IHC staining, however, was not found to be associated with any of the CRP SNPs or haplotypes. In univariate analyses, CRP IHC staining was significantly associated with high-CRP level TT genotypes of SNPs rs3091244 (OR 5.9, CI 1.20 - 28.87, p = 0.029) and rs1130864 (OR 5.9, CI 1.21 - 28.95, p = 0.028) (Figure [2](#F2){ref-type="fig"}). Individual haplotype (yes/no carriership) were not, but the haplotype pair TTGTC/TTGTC was significantly associated (OR = 5.5, CI = 1.03 - 29.48, p = 0.047) with CRP IHC staining. This relationship strengthened on inclusion of *APOE4*carriership and age as covariates (OR = 14.9, CI = 1.14 - 196.37, p = 0.040), however the CI were extremely large.

![**Co-localisation of CRP and Aβ immunohistochemical staining (a) Aβ staining (b) CRP staining (c) merge, 100 × magnification**.](1742-2094-8-96-1){#F1}

![***CRP*SNPs and prevalence of CRP immunohistochemical staining (positive/negative) with SNPs rs3091244 and rs1130864**. Genotypes in order of population frequency, with \* referring to \'no CRP staining\' versus \'positive staining\' with most common genotype as reference group.](1742-2094-8-96-2){#F2}

Multiple testing correction
---------------------------

We performed FDR calculations on our results, assuming that 11 independent tests were performed (6 SNPs and 5 haplotypes). These showed that with an FDR \< 0.05, or 5% false positives, most of our results were still applicable (see Table [4](#T4){ref-type="table"}). The SNPs and haplotypes of the *CRP*gene which were seen most often in analyses were rs2794521 (genotype CT), rs3091244 (genotypes TA and TT), rs3093075 (genotype CA) and haplotype TAGCC.

###### 

Results validated by FDR \< 0.05 cutoff limit

  p-value      SNP (and genotype) or Haplotype   Association
  ------------ --------------------------------- -------------------------------------------
  p\< 0.0001   n/a                               Aβ IHC and CRP IHC stainings (Chi square)
  p = 0.003    rs3093075 (genotype CA)           Increased risk of non-neuritic SP
  p = 0.007    rs3091244 (TA)                    Increased risk of non-neuritic SP
  p = 0.007    Haplotype (6) TAGCC               Increased risk of non-neuritic SP
  p = 0.037    rs2794521 (CT)                    Reduced risk of non-neuritic SP
  p = 0.076    rs1130864 (TT)                    Reduced risk of non-neuritic SP
  p = 0.076    Haplotype (4) TCGCT               Reduced risk of having NFT
  p = 0.080    rs3093075 (CA)                    Increased risk of neuritic SP
  p = 0.083    rs2794521 (CT)                    More likely to have CRP IHC staining
  p = 0.087    rs3093075 (CA)                    Less likely to have CRP IHC staining
  p = 0.090    Haplotype (6) TAGCC               Less likely to have CRP IHC staining
  p = 0.112    rs3091244 (TT)                    Reduced risk of non-neuritic SP
  p = 0.118    rs2794521 (CT)                    Reduced risk of neuritic SP

Discussion
==========

The mechanisms underlying AD have been sought for more than 100 years, with not more than a few risk factors being identified, and the development of therapeutics has been based on treating symptoms, rather than reversing or curing the disease. Increasing population and average lifespan will see the number of AD sufferers escalate, according to current estimates, which will stress healthcare and treatment services.

Common understanding relates SP (aggregations of amyloid-β (Aβ) protein) and NFT (accumulations of hyperphosphorylated tau protein) in the brains of AD subjects as causes of the disease, with both triggering inflammation and disrupting neuronal signalling, and SP also implicated in genetic mutations of familial AD \[[@B3]\]. Our recently published study \[[@B28]\] on the prevalence of these brain lesions suggests that they are much more frequent, and occur in younger individuals, than previously thought, although whether the disease process also begins earlier is yet to be ascertained.

The inflammation theory was developed after epidemiological studies revealed a 6-times smaller incidence of AD in a cohort of patients receiving NSAIDs for rheumatoid arthritis, compared to a control group \[[@B10],[@B33]\]. Whilst the effectiveness of NSAIDs is controversial in the treatment of AD \[[@B33]\], there is still a common consensus that inflammation is an important part of the AD process.

CRP is an acute phase inflammatory marker found in plasma. CRP levels have been shown to be upregulated in affected areas of AD brains \[[@B20]\]. Polymorphisms in the *CRP*gene associated with elevated CRP levels have been shown to increase mortality \[[@B22]\]. Research has implicated genetic factors as determining 27-40% of variance in plasma CRP levels \[[@B24],[@B25]\].

A relationship between *CRP*genotype and NFT was not seen in our cohort, as was also the case in our earlier study of *APOE*genotype \[[@B28]\]. NFT formation is presumed to be secondary to SP production \[[@B34]\]; thus the lack of an association with *CRP*genotypes and NFT and the idea that *CRP*polymorphisms would be related only to SP is consistent.

The findings of our current work that some high-CRP level polymorphisms correlate with early non-neuritic SP allows us to hypothesise that increased inflammatory levels may initiate or participate in the primary development of lesions, which then leads to other processes and damage to neurons, thus setting off a chain of events leading to AD. The absence of statistically significant associations between *CRP*genotypes and late-stage neuritic SP could be due to other factors acting upon SP development, such as effects of immune cells, including microglia \[[@B35],[@B36]\].

SNP rs2794521 has been previously reported to affect expression levels of CRP, with the T allele increasing transcription levels of the protein \[[@B24],[@B25]\] compared to the C allele. In our cohort, this was the only SNP that associated with the occurrence of SP, with the most common CT genotype showing borderline significance for an association with reduced risk of having at least one SP (p = 0.067). When we further analysed the associations, taking into account early or late SP phenotype, we found that *CRP*SNP rs2794521 (C carriers) was significantly associated with reduced risk of harbouring non-neuritic SP. It may be possible that the CT genotype associates with lower levels of CRP, thus interfering with formation of SP. In contrast, high-CRP level SNPs (rs3091244, TA carriers and rs3093075 CA carriers) were strongly associated with increased risk of non-neuritic SP. However as a sign of the complex relationship between SNPs and CRP levels, we found that other high-CRP level SNPs, rs1130864 (TT carriers) and rs1205 (CC carriers), also showed trends toward protection against non-neuritic SP compared to no SP. These results nonetheless suggest a role for the *CRP*gene, independent of *APOE*genotype, which was used as a covariate in these analyses.

The CCGCC haplotype contains the protective, low-CRP protein-linked C allele for both rs2794521 and rs3091244, whilst TAGCC has the high-CRP level T and A alleles for the same SNPs. The effects of these SNPs were corroborated in haplotype analyses showing that CCGCC carriership reduces risk and TAGCC carriership increases risk for non-neuritic SP, with tendencies in the same directions for neuritic SP compared to no SP. Our results, showing a correlation between CRP and Aβ IHC staining, support the involvement of inflammation in AD and correspond with other studies \[[@B20]\].

In line with previous reports and with our results above, the high-CRP SNP rs3091244 (TT genotype) was significantly associated with CRP IHC staining in the CA1/2 region. In contrast, the previously reported high-CRP level TT genotype of rs1130864 was significantly associated with positive staining, although our SP results would suggest it has some protective effect in non-neuritic SP formation. This could suggest that this SNP may confer more effective clean-up abilities, and that higher levels, in this case, are not detrimental.

The absence of an association between Aβ staining and *CRP*genotype could be explained if CRP affects only SP formation and not the presence of the Aβ peptide itself, which is the product of normal amyloid precursor protein processing \[[@B37]\]. This makes sense, given the revealed associations between *CRP*genotypes and SP types in our study.

As the majority of the TASTY series are non-AD cases, correlative findings between *CRP*genotypes and SP prevalence reveal an interesting insight into the early development of AD neuropathology. It is possible that these SP-positive cases could be in a prodromal phase of the disease and may later have developed AD, had they lived. We recently showed, however, that 31% of the subjects in this series harbour SP, and that this prevalence increased to almost 100% in the oldest old. This questions the relevance of SP prevalence and the relationship between these brain lesions and AD itself.

Our data suggest that *CRP*genotype may modify initial SP formation in the brain. This is an interesting finding that will need to be investigated further in cohorts comprising only of AD cases, and replicated in larger epidemiological studies. It may be that *CRP*polymorphisms associate with or participate in the slowing down or enhancement of early stage SP but, after this, other factors come into play to effect conversion to late-stage SP. As end-stage SP are more likely to be associated with dementia than other types \[[@B34]\], this could explain why NSAID treatments in clinical AD patients have proven ineffective at slowing or reversing the disease, as inflammation may already have played its part. Based on our studies and others\' results, the brains of most middle-aged to elderly persons possess some degree of persistent inflammation as well as SP and NFT. It could therefore be assumed that other factors aside from *CRP*genotype participate in the conversion of these \'benign\' SP, to pathological SP types related to AD.

Whilst it may be that the younger aged cases and consequential low numbers of SP may reduce power, and may have caused some of our results to represent false positives, our cohort is a large autopsy series, showing the prevalence of these brain lesions in a sample representative of a general non-institutionalised population.

Conclusions
===========

The common occurrence of these AD-related brain lesions and the subclinical elevations in elderly patients of inflammatory markers \[[@B38]\], as well as our current results, suggest that these are simply a consequence of brain aging without any relationship to clinical AD. The conversion of these pathways into those causing AD, however, are yet to be ascertained and remain controversial.
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